Argen-X

Webpage: www.argen-x.com

General description
arGEN-X is a publically traded therapeutic antibody biotechnology company. We have a proprietary SIMPLE AntibodyTM discovery platform that allows us to discover high affinity, high diversity antibody sets covering essentially all epitopes of a given target. arGEN-X combines active immunisation of llamas with Fab phage display to induce and harvest conventional antibody output of the immune response. In addition to the antibody discovery platform arGEN-X has three Fc modulation technologies: PK enhancement through NHance; Abdeg technology for driving autoimmune antibodies into destruction and finally arGEN-X has a licence for the PotelligentTM technology which can significantly enhance antibody dependent cytotoxicity and tumour cell killing activity.

Key research facilities, infrastructures and equipment
760m2 lab space, equipped with two BiaCore 3000 instruments, FACS machine, AKTA Purifier Llama immunisations are performed off-site under supervision of arGEN-X employees or consultants.

Project members  

  • Dr. Hans de Haard
  • Drs. Michael Saunders 

Follow us on

Hello everyone!
I am Noemi Karsai and I’m the next in our #ESR introduction series. I’m #ESR11 and I’m originally from Hungary, currently doing my PhD at @UoNLifeSci @COMPARE_UoBUoN, UK.

The transatlantic ECI GPCR symposium #ECIGPCR is about to start, we are ready!! Thanks to the organizers for their excellent job gathering almost 500 people across the globe! @cyclic_Andreas @NicoleAPerry1 @BenderSci @DesislavaNeshe1

My project will be focused on the role of #CXCR4/ACKR3/GRK2 -governed networks in cancer cell migration and metastasis.

Hello 🙂
I am here to continue the series in which all #ESRs are presenting themselves. I am Viviana Marolda and I am in my first year of PhD. I am #ESR13, originally from Italy, and currently, I am working as a PhD student in @CBMSO_CSIC_UAM, at Universidad Autonoma de Madrid.

Hey twitter!
I am @DehanComez. I am taking over the Oncornet account for a while to start a series of all #ESRs writing about themselves and their projects. I am #ESR5, originally from Turkey and right now I am working as a PhD student in @COMPARE_UoBUoN , @UniofNottingham , UK.

New review on #gpcr structural dynamics out in COSB. Great teamwork with the @JanaSelent group. Thanks to @Lundbeckfonden and @novonordiskfond https://lnkd.in/eyjrA5V

ONCORNET2.0 is the successor to #ONCORNET. You can see some of the work of ESRs from the first ONCORNET in this special issue of @MolPharmJournal from 2019, with reviews on #CXCR4 and #ACKR3 structure and function: https://molpharm.aspetjournals.org/content/96/6

Hi everyone – we’re on Twitter! ONCORNET2.0 is a #MarieCurie ITN of 16 ESRs across Europe studying #chemokine #GPCRs #CXCR4 and #ACKR3 in cancer. Our projects cover molecular dynamics, medchem, #pharmacology through to translational work. Follow us for updates from our ESRs!

Hi everyone!

Public service announcement: our Marie-Curie ITN @ONCORNET1 is on Twitter! The 16 wonderful #ECRs working on the project will soon be Tweeting about #GPCR #chemokine #ECR life and #pharmacology

Please #RT & consider a follow or follow back! 🙏😀

Load More…

Contact details

Please contact us at:
info@oncornet.eu

ONCORNET Coordinator
VU University Amsterdam
The Netherlands